HER2 Positivity, High Mitotic Rate, and Tumor Grade Are Associated With Pathologic Complete Response To Neoadjuvant Therapy in Breast Cancer

被引：0
|
作者：
Robinson, Brian [1 ]
O'Regan, Ruth [1 ]
Styblo, Toncred [1 ]
Li, Xiaoxian [1 ]
机构：
[1] Emory Univ, Atlanta, GA 30322 USA
来源：
LABORATORY INVESTIGATION | 2015年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
238
引用
收藏
页码：63A / 63A
页数：1
相关论文
共 50 条
  • [1] HER2 Positivity, High Mitotic Rate, and Tumor Grade Are Associated With Pathologic Complete Response To Neoadjuvant Therapy in Breast Cancer
    Robinson, Brian
    O'Regan, Ruth
    Styblo, Toncred
    Li, Xiaoxian
    MODERN PATHOLOGY, 2015, 28 : 63A - 63A
  • [2] Tumor infiltrating lymphocytes as a predictor of pathologic complete response to neoadjuvant therapy in HER2 positive breast cancer
    Chargoy, Alberto Monroy
    Verduzco-Aguirre, Haydee Cristina
    Chargoy, Javier Monroy
    Espinosa-Fernandez, Jose Rodrigo
    Ojeda, Jesus Antonio Martinez
    Cabrera-Galeana, Paula
    CANCER RESEARCH, 2024, 84 (09)
  • [3] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Meisel, Jane
    Suo, Aili
    Zhang, Chao
    Wei, Zhimin
    Aneja, Ritu
    Li, Zaibo
    Nahta, Rita
    Li, Xiaoxian
    MODERN PATHOLOGY, 2019, 32
  • [4] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Zhang, Chao
    Suo, Aili
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Krishnamurti, Uma
    Li, Xiaoxian
    MODERN PATHOLOGY, 2019, 32
  • [5] Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy
    Melissa Krystel-Whittemore
    Jin Xu
    Edi Brogi
    Katia Ventura
    Sujata Patil
    Dara S. Ross
    Chau Dang
    Mark Robson
    Larry Norton
    Monica Morrow
    Hannah Y. Wen
    Breast Cancer Research and Treatment, 2019, 177 : 61 - 66
  • [6] Pathologic complete response rate according to HER2 detection methods in HER2-positive breast cancer treated with neoadjuvant systemic therapy
    Krystel-Whittemore, Melissa
    Xu, Jin
    Brogi, Edi
    Ventura, Katia
    Patil, Sujata
    Ross, Dara S.
    Dang, Chau
    Robson, Mark
    Norton, Larry
    Morrow, Monica
    Wen, Hannah Y.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 177 (01) : 61 - 66
  • [7] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Zhang, Chao
    Suo, Aili
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Krishnamurti, Uma
    Li, Xiaoxian
    LABORATORY INVESTIGATION, 2019, 99
  • [8] Predictors of pathologic complete response in HER2 positive breast cancer patients treated with neoadjuvant targeted therapy
    Rosario, Mariela Huerta
    Sahoo, Sunati
    CANCER RESEARCH, 2020, 80 (04)
  • [9] Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
    Chen, Hai-Long
    Chen, Qiang
    Deng, Yong-Chuan
    MEDICINE, 2021, 100 (44)
  • [10] HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer
    Zhao, Jing
    Krishnamurti, Uma
    Zhang, Chao
    Meisel, Jane
    Wei, Zhimin
    Suo, Aili
    Aneja, Ritu
    Li, Zaibo
    Li, Xiaoxian
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (11)
12345